Coherus BioSciences (CHRS) Tops Q4 EPS by 20c
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.50 +1.35%
Revenue Growth %: +91.8%
Financial Fact:
Gain from sale of office premises: 0
Today's EPS Names:
CGEH, NAKA, APOG, More
Revenue Growth %: +91.8%
Financial Fact:
Gain from sale of office premises: 0
Today's EPS Names:
CGEH, NAKA, APOG, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q4 EPS of ($0.60), $0.20 better than the analyst estimate of ($0.80). Revenue for the quarter came in at $45.35 million versus the consensus estimate of $48.41 million.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
- Investing.com’s stocks of the week
- Benchmark Reiterates Buy Rating on Kura Sushi USA Inc. (KRUS) Ahead of Q3 Print
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
